GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Parnell Pharmaceuticals Holdings Ltd (OTCPK:PARNF) » Definitions » Price-to-Free-Cash-Flow

Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) Price-to-Free-Cash-Flow : N/A (As of Jun. 05, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Parnell Pharmaceuticals Holdings Price-to-Free-Cash-Flow?

As of today (2024-06-05), Parnell Pharmaceuticals Holdings's share price is $0.0001. Parnell Pharmaceuticals Holdings's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2018 was $-0.17. Hence, Parnell Pharmaceuticals Holdings's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Parnell Pharmaceuticals Holdings's Price-to-Free-Cash-Flow or its related term are showing as below:

PARNF's Price-to-Free-Cash-Flow is not ranked *
in the Drug Manufacturers industry.
Industry Median: 22.83
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Parnell Pharmaceuticals Holdings's Free Cash Flow per Share for the six months ended in Dec. 2018 was $-0.17. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-0.17.


Parnell Pharmaceuticals Holdings Price-to-Free-Cash-Flow Historical Data

The historical data trend for Parnell Pharmaceuticals Holdings's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Parnell Pharmaceuticals Holdings Price-to-Free-Cash-Flow Chart

Parnell Pharmaceuticals Holdings Annual Data
Trend Jun12 Jun13 Jun14 Dec15 Dec16 Dec17 Dec18
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial - - - - -

Parnell Pharmaceuticals Holdings Semi-Annual Data
Jun12 Jun13 Jun14 Dec15 Dec16 Dec17 Dec18
Price-to-Free-Cash-Flow Get a 7-Day Free Trial - - - - -

Competitive Comparison of Parnell Pharmaceuticals Holdings's Price-to-Free-Cash-Flow

For the Drug Manufacturers - Specialty & Generic subindustry, Parnell Pharmaceuticals Holdings's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Parnell Pharmaceuticals Holdings's Price-to-Free-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Parnell Pharmaceuticals Holdings's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Parnell Pharmaceuticals Holdings's Price-to-Free-Cash-Flow falls into.



Parnell Pharmaceuticals Holdings Price-to-Free-Cash-Flow Calculation

Parnell Pharmaceuticals Holdings's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=0.0001/-0.174
=N/A

Parnell Pharmaceuticals Holdings's Share Price of today is $0.0001.
For company reported annually, GuruFocus uses latest annual data as the TTM data. Parnell Pharmaceuticals Holdings's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2018 was $-0.17.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Parnell Pharmaceuticals Holdings  (OTCPK:PARNF) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Parnell Pharmaceuticals Holdings Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Parnell Pharmaceuticals Holdings's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) Business Description

Traded in Other Exchanges
N/A
Address
476 Gardeners Road, Unit 4, Century Estate, Alexandria, Sydney, NSW, AUS, 2015
Parnell Pharmaceuticals Holdings Ltd is an Australia based veterinary pharmaceutical company. It is focused on developing, manufacturing and commercializing animal health solutions. The group manufactures and market products for companion animals and production animals. The firm also has a pipeline of drug products like Zydax, PAR121 and PAR122 and Luminous which covers therapeutic areas in orthopedics, dermatology, and nutraceuticals. The operating segments of the company are Companion animal, Production animal - U.S., Production animal - rest of world and Contract Manufacturing. It operates internationally and generates the majority of the revenue from the Production animal - U.S. segment which covers the group's reproductive hormone portfolio across production animal in the USA.